Nabbing late-stage drug, PTC acquires gene therapy startup Agilis for $200M in cash/stock

After its bumpy road with a thrice-failed Duchenne drug, the team at PTC Therapeutics has been busy putting new irons in its fire. In its latest effort, the New Jersey company announced Thursday that it’s acquiring a gene therapy startup with a few promising drugs in its pipeline.